Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemotherapy in Blast Phase CML
NCT00023920Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2001
- Primary completion
- Sep 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in chronic myeloid leukemia (CML), sponsored by National Cancer Institute. Started Jul 2001; status: terminated.
02
Drugs
bevacizumab
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00023920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023920.